Literature DB >> 17138237

Percutaneous computed tomography-guided gastric remnant access after laparoscopic Roux-en-Y gastric bypass.

David Goitein1, Daniel J Gagné, Pavlos K Papasavas, Gordon McLean, Richard G Foster, H Scott Beasley, Philip F Caushaj.   

Abstract

BACKGROUND: The bypassed portion of the stomach is difficult to access and evaluate after Roux-en-Y gastric bypass. Access to the excluded stomach may be needed for nutritional support or decompression owing to acute distension and obstruction. We report our experience with percutaneous, computed tomography (CT)-guided gastrostomy tube placement into the gastric remnant after laparoscopic Roux-en-Y gastric bypass (LRYGB).
METHODS: Of 569 consecutive LRYGB procedures performed, 9 patients underwent successful percutaneous, CT-guided gastrostomy placement. One additional patient was referred from another facility. We reviewed the indications, interval from surgery to the intervention, interval to removal, complications, and success or outcome of the procedure in our patient population.
RESULTS: Ten patients underwent percutaneous, CT-guided gastric remnant gastrostomy tube placement. The indications included distended gastric remnant in 6, nutritional access in 4, and remnant drainage after leak in 1. Of the 10 patients, 2 had undergone previous gastric operations. The attempt at percutaneous gastrostomy was unsuccessful in 1 additional patient, who subsequently required laparoscopic gastrostomy (success rate 91%).
CONCLUSION: In selected patients after LRYGB, CT-guided gastrostomy tube placement is safe and efficient. It may be used to manage complications of LRYGB, serve as a bridge to definitive surgery, or offer a convenient route for enteral nutritional support.

Entities:  

Mesh:

Year:  2006        PMID: 17138237     DOI: 10.1016/j.soard.2006.09.007

Source DB:  PubMed          Journal:  Surg Obes Relat Dis        ISSN: 1550-7289            Impact factor:   4.734


  7 in total

1.  Epithelial cell turnover is increased in the excluded stomach mucosa after Roux-en-Y gastric bypass for morbid obesity.

Authors:  Adriana V Safatle-Ribeiro; Pedro A Petersen; Dilson S Pereira Filho; Carlos E P Corbett; Joel Faintuch; Robson Ishida; Paulo Sakai; Ivan Cecconello; Ulysses Ribeiro
Journal:  Obes Surg       Date:  2013-10       Impact factor: 4.129

2.  Direct Percutaneous Endoscopic Jejunostomy (DPEJ) Tube Placement: A Single Institution Experience and Outcomes to 30 Days and Beyond.

Authors:  Andrew T Strong; Gautam Sharma; Matthew Davis; Michael Mulcahy; Suriya Punchai; Colin P O'Rourke; Stacy A Brethauer; John Rodriguez; Jeffrey L Ponsky; Matthew D Kroh
Journal:  J Gastrointest Surg       Date:  2016-12-19       Impact factor: 3.452

3.  Surgical gastrostomy for pancreatobiliary and duodenal access following Roux en Y gastric bypass.

Authors:  Jessica M Gutierrez; Howard Lederer; Jon C Krook; Timothy P Kinney; Martin L Freeman; Eric H Jensen
Journal:  J Gastrointest Surg       Date:  2009-09-24       Impact factor: 3.452

4.  Laparoscopic gastric bypass with subtotal gastrectomy for a super-obese patient with Biermer anemia.

Authors:  Maxime Sodji; Frédéric A Sebag; Jean Marc Catheline
Journal:  Obes Surg       Date:  2007-08       Impact factor: 4.129

Review 5.  Choledocholithiasis after Bariatric Surgery-More than a Stone's Throw to Reach?

Authors:  Krishnamurthy Somasekar; David S Y Chan; Nhatuveetil S Sreekumar; Salman Anwer
Journal:  J Gastrointest Surg       Date:  2017-11-30       Impact factor: 3.452

Review 6.  Acute complications after laparoscopic bariatric procedures: update for the general surgeon.

Authors:  Fabio Cesare Campanile; Cristian E Boru; Mario Rizzello; Alessandro Puzziello; Catalin Copaescu; Giuseppe Cavallaro; Gianfranco Silecchia
Journal:  Langenbecks Arch Surg       Date:  2013-03-22       Impact factor: 3.445

7.  Routine gastrostomy tube placement in gastric bypass patients: impact on length of stay and 30-day readmission rate.

Authors:  Rena Moon; Andre Teixeira; Kelly Potenza; Muhammad A Jawad
Journal:  Obes Surg       Date:  2013-02       Impact factor: 4.129

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.